Table of Contents

Drug Discovery and Translational Medicine

• Open Access

  Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer’s Disease

  Edilio Borroni, Bernd Bohrmann, Fiona Grueninger, Eric Prinssen, Stephane Nave, Hansruedi Loetscher, Shankar J Chinta, Subramanian Rajagopalan, Anand Rane, Almas Siddiqui, Bart Ellenbroek, Juerg Messer, Axel Pähler, Julie K Andersen, Rene Wyler and Andrea M Cesura

  Journal of Pharmacology and Experimental Therapeutics September 2017, 362 (3) 413-423; DOI: https://doi.org/10.1124/jpet.117.241653
• You have access

  Optimization of Thermolytic Response to A₁ Adenosine Receptor Agonists in Rats

  Isaac R. Bailey, Bernard Laughlin, Lucille A. Moore, Lori K. Bogren, Zeinab Barati and Kelly L. Drew

  Journal of Pharmacology and Experimental Therapeutics September 2017, 362 (3) 424-430; DOI: https://doi.org/10.1124/jpet.117.241315
• You have access

  Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice

  Shinji Iwasaki, Teruki Hamada, Ikumi Chisaki, Tomohiro Andou, Noriyasu Sano, Atsutoshi Furuta and Nobuyuki Amano

  Journal of Pharmacology and Experimental Therapeutics September 2017, 362 (3) 441-449; DOI: https://doi.org/10.1124/jpet.117.242651
• You have access

  The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468

  Alexander Treiber, Ruben de Kanter, Catherine Roch, John Gatfield, Christoph Boss, Markus von Raumer, Benno Schindelholz, Clemens Muehlan, Joop van Gerven and Francois Jenck

  Journal of Pharmacology and Experimental Therapeutics September 2017, 362 (3) 489-503; DOI: https://doi.org/10.1124/jpet.117.241596